Philip Levy
Endocrinology, Diabetes & Metabolism · Phoenix, AZNPI 1700902053
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (58.1%), food and beverage and education — rather than concentrated in one kind of arrangement. 36 manufacturers reported payments, led by Sanofi-aventis U.S. LLC at 40.1% of the total. Reporting peaked in 2019 at $5,480 and has fallen 92.2% since, to $428 in 2022.
Across 182 payments — averaging $48.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi-aventis U.S. LLC$4K
- Novo Nordisk$2K
- Boehringer Ingelheim$424
- Mannkind Corporation$351
- Lilly USA, LLC$283
- AstraZeneca$214
- plus $2K from 30 others
Across 1 payment — averaging $592.94 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Merck$593
What the payments were for
- Consulting fees$5,16058%
- Food & beverage$3,71042%
- Education$180%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi-aventis U.S. LLC | 15 | $3,568 |
| Novo Nordisk | 21 | $2,467 |
| Boehringer Ingelheim | 21 | $424 |
| Mannkind Corporation | 16 | $351 |
| Lilly USA, LLC | 20 | $283 |
| AstraZeneca | 14 | $214 |
| Insulet Corporation | 8 | $153 |
| AbbVie(2 entities) | 9 | $148 |
| Amarin Pharma, Inc. | 2 | $132 |
| Merck | 7 | $130 |
| Janssen Scientific Affairs, LLC | 1 | $123 |
| Abbott | 6 | $109 |
| Shire North American Group Inc | 5 | $85 |
| Amgen | 4 | $78 |
| Regeneron | 1 | $72 |
| Corcept Therapeutics | 4 | $59 |
| Radius Health, Inc. | 3 | $53 |
| Regeneron Healthcare Solutions, Inc. | 1 | $52 |
| Dexcom, Inc. | 2 | $51 |
| Lifescan, Inc. | 2 | $45 |
| Johnson & Johnson | 4 | $44 |
| Medtronic | 2 | $38 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $21 |
| Xeris Pharmaceuticals, Inc. | 1 | $19 |
| Endo Pharmaceuticals Inc. | 1 | $18 |
| Tandem Diabetes Care, Inc. | 1 | $18 |
| Bayer | 1 | $17 |
| Ipsen Biopharmaceuticals, Inc | 1 | $16 |
| GRT US Holding, Inc. | 1 | $15 |
| Antares Pharma, Inc. | 1 | $15 |
| Jazz Pharmaceuticals Inc. | 1 | $13 |
| Vistapharm, Inc. | 1 | $13 |
| Companion Medical, Inc. | 1 | $13 |
| Apria Healthcare LLC | 1 | $12 |
| Aytu Biopharma, Inc. | 1 | $11 |
| Vivus LLC | 1 | $10 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$8,888 in reported general payments places this provider in the 75th percentile of 148 endocrinology, diabetes & metabolism providers in Arizona.
See all endocrinology, diabetes & metabolism providers in Arizona →
Other endocrinology, diabetes & metabolism in Phoenix
- Kevin YuenPhoenix$404K
- Joan BaileyPhoenix$316K
- Anna BoronPhoenix$32K
- Kari EdlingPhoenix$23K
- James DeerPhoenix$13K
- Lory BarazPhoenix$10K
- Sathya JyothinagaramPhoenix$10K
- Richard ArakakiPhoenix$6K
- Yasmin AkhunjiPhoenix$5K
- Ahmad Al MaradniPhoenix$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.